These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 23022163)

  • 1. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
    Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
    Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Mathew R; Pearce E; Sivaprasad S
    Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results.
    Parravano M; Oddone F; Tedeschi M; Chiaravalloti A; Perillo L; Boccassini B; Varano M
    Retina; 2010; 30(7):1017-24. PubMed ID: 20224469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifocal pupillography identifies ranibizumab-induced changes in retinal function for exudative age-related macular degeneration.
    Sabeti F; Maddess T; Essex RW; James AC
    Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):253-60. PubMed ID: 22159011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab.
    Grenga PL; Fragiotta S; Meduri A; Lupo S; Marenco M; Vingolo EM
    Can J Ophthalmol; 2013 Oct; 48(5):394-9. PubMed ID: 24093186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year follow-up of functional recovery in neovascular AMD during monthly anti-VEGF treatment.
    Munk MR; Kiss C; Huf W; Sulzbacher F; Roberts P; Mittermüller TJ; Sacu S; Simader C; Schmidt-Erfurth U
    Am J Ophthalmol; 2013 Oct; 156(4):633-43. PubMed ID: 23891335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
    Yodoi Y; Tsujikawa A; Nakanishi H; Otani A; Tamura H; Ojima Y; Hayashi H; Yoshimura N
    Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R; Richardson M; Sivaprasad S
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
    Scupola A; Tiberti AC; Sasso P; Savastano MC; Mastrocola A; Marangoni D; Minnella AM; Falsini B; Balestrazzi E
    Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
    Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
    Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.